Ben Rome
@bnrome
PCP @BrighamWomens, researcher @PORTAL_Research studying 💊💰📈. Alum @BrighamMedRes @harvardmed @HarvardChanSPH @BrownUniversity. Views my own.
ID: 428673712
https://www.portalresearch.org/benjamin-rome.html 05-12-2011 01:48:38
2,2K Tweet
1,1K Followers
1,1K Following
The latest The Journal of Law, Medicine & Ethics is now available, featuring "Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable," by Hwang, Aaron Kesselheim, and Ben Rome. Please take a look! Program On Regulation, Therapeutics, And Law ASLME Harvard Medical School cambridge.org/core/journals/…
Check out all the latest great work being done here at Program On Regulation, Therapeutics, And Law! 👀
Do U love Rx data, are U an experienced researcher focused on policy, do U care about Rx affordability? Come work w/MN's Pharmaceutical Economics Research team! mn.gov/mmb/careers/, job# 77354. NASHP, Stacie Dusetzina, 46brooklyn Research, Ben Rome, Sayeh Nikpay; USC Schaeffer Center
Excellent takes by Joey Matingly. Blaming PBMs for everything is an oversimplification. Hopefully Rebecca Robbins can incorporate some of this nuance in the rest of the PBM series.
For those attending AcademyHealth #ARM24 , come check out what Program On Regulation, Therapeutics, And Law has been up to with some posters and presentations by me and Christopher Cai, MD!
Great to see so many Brigham and Women's Medicine Residents alumni at #ARM! 💪 Others not pictured: Jessica Lee Jose Figueroa, MD, MPH Rishi Wadhera, MD MPP Lisa Rotenstein MD Walid Gellad Michael L. Barnett Michael McWilliams Aaron Schwartz Christopher Cai, MD
Using the U.S. FDA Drug Shortage List in November 2023, we identified 117 drugs in shortage. 20% of drugs in shortage are generic (off-patent), essential for public health (listed on World Health Organization (WHO) list) and made by 3 or fewer manufacturers (limited competition). Here's a list! 2/
In JAMA Health Forum, Catherine Hwang, Hussain Lalani, MD, MPH, MSc & Ben Rome discuss state efforts to set drug spending targets. They outline the limitations of using this policy to address high drug spending, absent a more robust approach to improve affordability. jamanetwork.com/journals/jama-…
I didn’t realize a new season of Succession was coming out so soon! nytimes.com/2024/07/24/bus…
In their new Forefront article, Suhas Gondi, Ben Rome + William H. Shrank from Brigham and Women's Hospital + Humana argue that, as regulators consider how mergers involving PBMs affect competition, they should also consider the clinical and financial benefits for patients. bit.ly/3WvYEzt
Analysis led by Dongzhe Hong in Health Affairs examined the patient & prescriber factors impacting US #biosimilar use from 2013-2022, including geography, patient age, prescriber type, & where the drug was administered. healthaffairs.org/doi/10.1377/hl…